COMPARATIVE EFFICACY AND SAFETY OF ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA USING A MATCHING-ADJUSTED INDIRECT COMPARISON

被引：0
|
作者：
Leleu, X. [1 ]
Delea, T. [2 ]
Guyot, P. [3 ]
Moynahan, A. [2 ]
Singh, E. [4 ]
Tekle, C. [4 ]
Lin, P. [4 ]
机构：
[1] Univ Poitiers Hosp, Poitiers, France
[2] Policy Anal Inc, Brookline, MA USA
[3] Sanofi, Paris, France
[4] Sanofi, Cambridge, MA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC34
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [1] Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
    Leleu, Xavier
    Delea, Thomas
    Guyot, Patricia
    Moynahan, Aaron
    Singh, Erin
    Tekle, Christina
    Lin, Peggy L.
    BLOOD, 2023, 142
  • [2] A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma
    Richter, Joshua
    Lin, Peggy
    Garcia-Horton, Viviana
    Guyot, Patricia
    Singh, Erin
    Zhou, Zheng-Yi
    Sievert, Mark
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S157
  • [3] Matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma
    Richter, Joshua
    Lin, Peggy L.
    Garcia-Horton, Viviana
    Guyot, Patricia
    Singh, Erin
    Zhou, Zheng-Yi
    Sievert, Mark
    Taiji, Riley
    CANCER MEDICINE, 2023, 12 (07): : 8005 - 8017
  • [4] Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison
    Van Sanden, Suzy
    Ito, Tetsuro
    Diels, Joris
    Vogel, Martin
    Belch, Andrew
    Oriol, Albert
    ONCOLOGIST, 2018, 23 (03): : 279 - 287
  • [5] Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes of Isatuximab Plus Carfilzomib and Dexamethasone Versus Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
    Richter, Joshua
    Lin, Peggy L.
    Garcia-Horton, Viviana
    Guyot, Patricia
    Zhou, Zheng-Yi
    Sievert, Mark
    BLOOD, 2023, 142
  • [6] COMPARATIVE EFFICACY OF DARATUMUMAB MONOTHERAPY AND POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE (POMA plus LODEX) IN THE TREATMENT OF MULTIPLE MYELOMA : A MATCHING ADJUSTED INDIRECT COMPARISON (MAIC)
    van Sanden, S.
    Ito, T.
    Vogel, M.
    Diels, J.
    VALUE IN HEALTH, 2016, 19 (07) : A713 - A714
  • [7] Matching-Adjusted Indirect Comparison of Relative Efficacies Is Feasible and Useful in the Multiple Myeloma Therapy Landscape: A Comparison of Pomalidomide Plus Low-Dose Dexamethasone Versus Daratumumab
    Parikh, Kejal
    Proskorovsky, Irina
    Abouzaid, Safiya
    Krotneva, Stanimira
    Page, Veronique
    Pelligra, Christopher G.
    Guo, Shien
    Mouro, Jorge L.
    Ailawadhi, Sikander
    BLOOD, 2016, 128 (22)
  • [8] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [9] Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
    Richardson, Paul G.
    Attal, Michel
    Campana, Frank
    Le-Guennec, Solenn
    Hui, Ai-Min
    Risse, Marie-Laure
    Corzo, Kathryn
    Anderson, Kenneth C.
    FUTURE ONCOLOGY, 2018, 14 (11) : 1035 - 1047
  • [10] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Richardson, Paul G.
    Facon, Thierry
    Bensinger, William I.
    Leleu, Xavier
    Campana, Frank
    Mace, Sandrine
    Chiron, Marielle
    van de Velde, Helgi
    Mikhael, Joseph
    BLOOD CANCER JOURNAL, 2021, 11 (03)
12345